Clinical trials: Partial Epilepsy, open to volunteers
Epilepsies, Epilepsies, Focal
Home Ultra-long Term EEG Monitoring for Rare Epilepsies and Developmental and Epileptic Encephalopathies
With this study the Investigator expects to develop a precise patient-centered model of care by means of home ultra-long-term EEG monitoring with a minimally invasive wearable EEG device (sqEEG).
- Conditions
- Epilepsies, Epilepsies, Focal, Epileptic Encephalopathy
- Trial name
- EMIRE (NCT06855901)
- Testing
- Ultra-longterm EEG monitoring at home by means of a scubscalp electrode implant.
- Where
- 4 sites in Italy
- Volunteers
- 30 people
- Sponsor
- Azienda Ospedaliero-Universitaria di Modena
Epilepsy, Drug Resistant
Extreme Capsule Electrical Stimulation for Drug-resistant Focal Epilepsy
Evaluation of the Efficacy and Safety of Deep Brain Stimulation of the Extreme Capsule (EC) for the Treatment of Drug-Resistant Epilepsy
- Trial name
- NCT06663124
- Testing
- EC-DBS ON
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Xuanwu Hospital, Beijing
Epilepsy, Focal Epilepsy
Cognitive Impairment in Drug-resistant and Drug-responsive Focal Cryptogenic Epilepsy
This is a national monocentric (San Raffaele Hospital - OSR, Via Olgettina, 60, 20132 Milan, Italy) observational low-risk-intervention study, prospective and multiparametric (clinical, EEG, neuropsychological evaluations) study.
- Trial name
- NCT06210022
- Testing
- Neuropsychological Assessment
- Where
- Italy
- Volunteers
- 130 people
- Sponsor
- IRCCS San Raffaele
Refractory Epilepsy, Focal Epilepsy
Atlas of Human Cognition by SEEG (MAPCOG-SEEG)
The main objective of MAPCOG_SEEG is to create a database including brain recordings of cognition performed in clinical routine in patients during the pre-surgical SEEG assessment.
- Trial name
- MAPCOG-SEEG (NCT03644732)
- Testing
- SEEG Group
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Grenoble
Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy)
Congenital Muscle Disease Study of Patient and Family Reported Medical Information
The Congenital Muscle Disease Patient and Proxy Reported Outcome Study (CMDPROS) is a longitudinal 10 year study to identify and trend care parameters, adverse events in the congenital muscle diseases using the Congenital Muscle…
- Conditions
- Congenital Muscular Dystrophy With ITGA7 (Integrin Alpha-7) Deficiency, Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy and Abnormal Glycosylation of Dystroglycan With Severe Epilepsy), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Fatty Liver and Infantile-onset Cataract Caused by TRAPPC11 Mutations), Alpha-Dystroglycanopathy (Congenital Muscular Dystrophy With Hypoglycosylation of Dystroglycan)
- Trial name
- CMDPROS (NCT01403402)
- Where
- United States
- Volunteers
- 4,000 people
- Sponsor
- Cure CMD